Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

Annals of Neurology

Volumn 68, Issue 3, 2010, Pages 409-411

  Berger, Joseph R ^a   Centonze, Diego ^b   Comi, Giancarlo ^c   Confavreux, Christian ^d   Cutter, Gary ^e   Giovannoni, Gavin ^f   Gold, Ralf ^g   Hartung, Hans Peter ^h   Lublin, Fred ⁱ   Miravalle, Augusto ^j   Montalban, Xavier ^k   O'Connor, Paul ^l   Olsson, Tomas ^m   Polman, Chris H ⁿ   Stuve, Olaf ^o   Wolinsky, Jerry S ^p   Ziemssen, Tjalf ^q  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d HÔPITAL NEUROLOGIQUE   (France)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Department of Neurology The Barts ^*  (United Kingdom)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l ST MICHAEL'S HOSPITAL   (Canada)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ VU UNIVERSITY AMSTERDAM   (Netherlands)

^o UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^p UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^q DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA INTERFERON; GLATIRAMER; NATALIZUMAB; NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY;

CLINICAL EVALUATION; DISEASE ACTIVITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; ENCEPHALITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKOCYTE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REBOUND; RECURRENT DISEASE; RELAPSE; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MULTIPLE SCLEROSIS;

EID: 77956377928     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22083     Document Type: Letter

References (8)

1. Perumal J, Hreha S, Bao F, et al. Post-natalizumab associated rebound or CNS immune reconstitution syndrome: clinical and MRI findings. Mult Scler 2009;15:S119.
2. Pesci I, Manneschi L, Guareschi A, Montanari E. Stopping natalizumab therapy: what happens. An Italian MS centre experience, Fidenza. Mult Scler 2009;15:S121.
3. Haartsen J, Butzkueven H, Marriott M. Early relapses after the first dose of natalizumab in active multiple sclerosis. Mult Scler 2009;15:S245.
4. Perini P, Rinaldi F, Rinaldi L, et al. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis. Mult Scler 2009;15:S234.
5. Miravalle A, Jensen R, Kinkel R. Immune reconstitution syndrome in multiple sclerosis patients following cessation of natalizumab therapy. Mult Scler 2009;15:1398.
6. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008;70:1150-1151. (Pubitemid 351464749)
7. O'Connor PW, Goodman AD, Kappos L, et al. Return of disease activity after cessation of natalizumab therapy in patients with multiple sclerosis. Mult Scler 2009;15:S240-S241.
8. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23. (Pubitemid 36026342)